Award
National Cancer Institute 10916490
Development of a novel small molecule RPN13 inhibitor and therapeutic for advanced ovarian cancer patients
Recipient
UP THERAPEUTICS, INC.
Award Amount
$1,178,998.00
Ceiling
$1,178,998.00
Awarded
July 31, 2024
Identifier
10916490
Award for developing a novel small molecule RPN13 inhibitor as a therapeutic for advanced ovarian cancer, funded by the National Cancer Institute.
Description
The project involves developing a small molecule RPN13 inhibitor for ovarian cancer, including toxicity assessment, efficacy testing, process development, and safety studies. The funding is provided by the National Cancer Institute to support an IND application to the FDA.